总结陈述：分子标志物检测在甲状腺癌中的应用。
Summary statement: utility of molecular marker testing in thyroid cancer.
机构信息
Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
出版信息
Surgery. 2010 Dec;148(6):1313-5. doi: 10.1016/j.surg.2010.09.023.
Abstract
The use of molecular markers for thyroid cancer diagnosis, prognosis, and surveillance have been an exciting area of study and change. Recent investigative focus on promising new markers will very likely lead to improvements in the diagnostic utility of fine needle aspiration biopsy (FNAB) in predicting malignancy, as well as provide more accurate prognostic information pre- and postoperatively. The 2010 Annual Meeting of the American Association for Endocrine Surgeons featured a symposium dedicated to molecular marker testing in thyroid cancer and its potential clinical applicability.
摘要
分子标志物在甲状腺癌的诊断、预后和监测中的应用一直是一个令人兴奋的研究领域，发生了很多变化。最近，研究的重点集中在有前途的新标志物上，这很可能会提高细针穿刺活检（FNAB）在预测恶性肿瘤方面的诊断效用，并提供更准确的术前和术后预后信息。美国内分泌外科学会 2010 年年会的一个专题研讨会专门讨论了甲状腺癌的分子标志物检测及其潜在的临床应用。
相似文献
1
Summary statement: utility of molecular marker testing in thyroid cancer.总结陈述：分子标志物检测在甲状腺癌中的应用。
Surgery. 2010 Dec;148(6):1313-5. doi: 10.1016/j.surg.2010.09.023.
2
Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.甲状腺恶性肿瘤的疾病多基因诊断及范围检测
Cancer. 2006 Jun 15;106(12):2592-7. doi: 10.1002/cncr.21922.
3
A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy.一项前瞻性研究评估了联合临床因素和候选诊断标志物用于提高甲状腺细针抽吸活检准确性的准确性。
Surgery. 2010 Dec;148(6):1170-6; discussion 1176-7. doi: 10.1016/j.surg.2010.09.025.
4
Circulating thyroid cancer markers.循环甲状腺癌标志物
Curr Opin Endocrinol Diabetes Obes. 2007 Oct;14(5):383-8. doi: 10.1097/MED.0b013e3282eeb2f4.
5
Thyroglobulin measurements in washouts of fine-needle aspiration biopsy in the monitoring of patients with differentiated thyroid carcinoma.细针抽吸活检洗脱液中甲状腺球蛋白的测量在分化型甲状腺癌患者监测中的应用。
Endokrynol Pol. 2021;72(6):601-608. doi: 10.5603/EP.a2021.0077. Epub 2021 Oct 14.
6
Preoperative serum thyroglobulin as an adjunct to fine-needle aspiration in predicting well-differentiated thyroid cancer.术前血清甲状腺球蛋白作为细针穿刺的辅助手段预测分化型甲状腺癌。
J Otolaryngol Head Neck Surg. 2010 Dec;39(6):669-73.
7
Fine Needle Biopsy Versus Core Needle Biopsy Combined With/Without Thyroglobulin or BRAF 600E Mutation Assessment for Detecting Cervical Nodal Metastasis of Papillary Thyroid Carcinoma.细针穿刺活检与核心针活检联合/不联合甲状腺球蛋白或 BRAF 600E 突变评估用于检测甲状腺乳头状癌颈部淋巴结转移。
Front Endocrinol (Lausanne). 2021 Apr 12;12:663720. doi: 10.3389/fendo.2021.663720. eCollection 2021.
8
Non-diagnostic rates for thyroid fine needle aspiration are negatively correlated with positive for malignancy rates.
Acta Cytol. 2011;55(1):38-41. doi: 10.1159/000320910. Epub 2010 Nov 26.
9
Diagnostic accuracy of fine needle aspiration biopsy for detection of malignancy in pediatric thyroid nodules: protocol for a systematic review and meta-analysis.细针穿刺活检对小儿甲状腺结节恶性肿瘤检测的诊断准确性：系统评价与Meta分析方案
Syst Rev. 2015 Sep 24;4:120. doi: 10.1186/s13643-015-0109-0.
10
Thyroglobulin in the washout fluid of lymph-node biopsy: what is its role in the follow-up of differentiated thyroid carcinoma?甲状腺球蛋白在淋巴结活检洗脱液中的作用：在分化型甲状腺癌的随访中其作用如何？
Thyroid. 2014 Jan;24(1):7-18. doi: 10.1089/thy.2013.0244. Epub 2013 Oct 29.
引用本文的文献
1
The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.贝塞斯达分类法在预测甲状腺乳头状癌分期中的效用及其与BRAF突变的关联。
Langenbecks Arch Surg. 2017 Mar;402(2):227-234. doi: 10.1007/s00423-017-1560-2. Epub 2017 Feb 3.
2
Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.甲状腺结节的组织学诊断与突变组检测之间的相关性：一项为期两年的机构经验
Thyroid. 2016 Aug;26(8):1068-76. doi: 10.1089/thy.2016.0048. Epub 2016 Jul 12.
3
BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.BRAF（V600E）突变、RET/PTC1和PAX8-PPARγ重排在滤泡上皮源性甲状腺病变中的研究——机构经验及文献综述
Balkan Med J. 2015 Apr;32(2):156-66. doi: 10.5152/balkanmedj.2015.15101. Epub 2015 Apr 1.
4
5
Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.即使甲状腺结节没有显示可疑的超声特征，额外的BRAF突变分析对于仅具有“可疑恶性”细胞学特征的甲状腺结节可能具有额外的诊断价值。
Endocrine. 2014 Sep;47(1):283-9. doi: 10.1007/s12020-013-0150-5. Epub 2014 Jan 23.
6
DNA copy number variations characterize benign and malignant thyroid tumors.DNA 拷贝数变异可用于区分良恶性甲状腺肿瘤。
J Clin Endocrinol Metab. 2013 Mar;98(3):E558-66. doi: 10.1210/jc.2012-3113. Epub 2013 Jan 23.
7
Well-differentiated thyroid carcinomas: management of the central lymph node compartment and emerging biochemical markers.分化型甲状腺癌：中央区淋巴结处理及新兴生化标志物。
J Oncol. 2011;2011:705305. doi: 10.1155/2011/705305. Epub 2011 Sep 29.
8
Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs.难以诊断的甲状腺组织学亚型的表达谱分析显示出独特的表达谱，并鉴定出候选诊断 microRNA。
Ann Surg Oncol. 2011 Nov;18(12):3443-52. doi: 10.1245/s10434-011-1766-4. Epub 2011 May 7.
本文引用的文献
1
Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples.循环促甲状腺激素受体 mRNA 作为甲状腺癌的一种新型标志物：来自 1758 个样本的临床应用经验。
Ann Surg. 2010 Oct;252(4):643-51. doi: 10.1097/SLA.0b013e3181f5ba51.
2
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.B-Raf(V600E) 和血小板反应蛋白-1 促进甲状腺癌进展。
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. doi: 10.1073/pnas.1004934107. Epub 2010 May 24.
3
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.在甲状腺结节的细胞学标本中检测原癌基因突变可提高细胞学诊断的准确性。
J Clin Endocrinol Metab. 2010 Mar;95(3):1365-9. doi: 10.1210/jc.2009-2103. Epub 2010 Feb 3.
4
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.优化与BRAF突变相关的甲状腺乳头状癌的手术治疗
Surgery. 2009 Dec;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011.
5
Molecular diagnostics and predictors in thyroid cancer.甲状腺癌的分子诊断和预测因子。
Thyroid. 2009 Dec;19(12):1351-61. doi: 10.1089/thy.2009.0240.
6
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.美国甲状腺协会修订的甲状腺结节和分化型甲状腺癌患者管理指南。
Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110.
7
Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.突变型 BRAF(T1799A) 可在甲状腺乳头状癌患者的血液中被检测到，并与疾病状态相关。
J Clin Endocrinol Metab. 2009 Dec;94(12):5001-9. doi: 10.1210/jc.2009-1349. Epub 2009 Oct 22.
8
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.用于甲状腺乳头状癌术前风险分层的甲状腺细针穿刺活检标本的BRAF突变检测
J Clin Oncol. 2009 Jun 20;27(18):2977-82. doi: 10.1200/JCO.2008.20.1426. Epub 2009 May 4.
9
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.分子检测在改善甲状腺结节细针穿刺诊断中对突变的检测作用。
J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8. doi: 10.1210/jc.2009-0247. Epub 2009 Mar 24.
10
Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.外周促甲状腺素受体mRNA在分化型甲状腺癌随访中的有效性
Ann Surg Oncol. 2009 Feb;16(2):473-80. doi: 10.1245/s10434-008-0211-9. Epub 2008 Nov 18.
Zotero 插件